Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ
暂无分享,去创建一个
D. Dabbs | C. Shah | P. Whitworth | S. Shivers | T. Bremer | Jess Savala | Karuna Mittal | Scott Heineman
[1] M. Moran,et al. Risk Assessment in the Molecular Era. , 2022, Seminars in radiation oncology.
[2] F. Vicini,et al. Assessing the benefit of adjuvant endocrine therapy in patients following breast-conserving surgery with or without radiation stratified by a 7-gene predictive DCIS biosignature. , 2022, Journal of Clinical Oncology.
[3] F. Vicini,et al. Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS) , 2021, Cancers.
[4] Barbara L. Smith,et al. Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804 , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] F. Vicini,et al. A novel biosignature identifies DCIS patients with a poor biologic subtype with an unacceptably high rate of local recurrence after breast conserving surgery and radiotherapy. , 2021 .
[6] Rakesh R. Patel,et al. Correction to: The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery , 2021, Annals of Surgical Oncology.
[7] Rakesh R. Patel,et al. The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery , 2021, Annals of Surgical Oncology.
[8] S. Pinder,et al. Variability in grading of ductal carcinoma in situ among an international group of pathologists , 2021, The journal of pathology. Clinical research.
[9] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[10] P. V. van Diest,et al. Grading variation in 2,934 patients with ductal carcinoma in situ of the breast: the effect of laboratory- and pathologist-specific feedback reports , 2020, Diagnostic Pathology.
[11] Rakesh R. Patel,et al. Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy , 2020, Clinical Cancer Research.
[12] A. Raldow,et al. Cost Effectiveness of DCISionRT for Guiding Treatment of Ductal Carcinoma in Situ , 2020, JNCI cancer spectrum.
[13] M. Torres. Genomic Assays to Assess Local Recurrence Risk and Predict Radiation Therapy Benefit in Patients With Ductal Carcinoma In Situ. , 2019, International journal of radiation oncology, biology, physics.
[14] L. Solin. Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions , 2019, Current Oncology Reports.
[15] Rakesh R. Patel,et al. A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk , 2018, Clinical Cancer Research.
[16] J. Benson,et al. Management of ductal carcinoma in situ in the modern era. , 2018, Minerva chirurgica.
[17] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[18] Li-Tai Hu,et al. YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer , 2017, Journal of Experimental & Clinical Cancer Research.
[19] Rinku Sutradhar,et al. Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ , 2017, Journal of the National Cancer Institute.
[20] A. Barrio,et al. Controversies in the Treatment of Ductal Carcinoma in Situ. , 2017, Annual review of medicine.
[21] R. Gray,et al. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Shak,et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone , 2015, Breast Cancer Research and Treatment.
[23] Marius Raica,et al. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. , 2015, Anticancer research.
[24] Barbara L. Smith,et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Lara J. Monteiro,et al. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer , 2014, Oncogene.
[26] L. Holmberg,et al. Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial , 2014 .
[27] Linda A Bradley,et al. Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. , 2014, Archives of pathology & laboratory medicine.
[28] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[29] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Margaret E McLaughlin-Drubin,et al. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines , 2013, Proceedings of the National Academy of Sciences.
[31] G. Schwartz,et al. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. , 2011, The American journal of pathology.
[32] J. Palazzo,et al. Prognostic markers and long‐term outcomes in ductal carcinoma in situ of the breast treated with excision alone , 2011, Cancer.
[33] H. Kuerer,et al. Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review , 2011, Journal of Cancer.
[34] R. Kane,et al. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis , 2011, Breast Cancer Research and Treatment.
[35] R. Peto,et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. , 2010, Journal of the National Cancer Institute. Monographs.
[36] Edi Brogi,et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Karla Kerlikowske,et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.
[38] R. Kane,et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. , 2010, Journal of the National Cancer Institute.
[39] M. Pike,et al. National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. , 2010, Journal of the National Cancer Institute.
[40] M. Hung,et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines , 2010, Breast cancer : basic and clinical research.
[41] T. Wilt,et al. Diagnosis and management of ductal carcinoma in situ (DCIS). , 2009, Evidence report/technology assessment.
[42] M. Cooper,et al. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ , 2008, World journal of surgical oncology.
[43] F. Schmidt. Meta-Analysis , 2008 .
[44] E. Rakovitch,et al. Biological Markers Predictive of Invasive Recurrence in DCIS , 2008, Clinical medicine. Oncology.
[45] Karla Kerlikowske,et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. , 2007, Cancer cell.
[46] T. Hieken,et al. Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up. , 2007, American journal of surgery.
[47] J. Wesseling,et al. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. , 2007, The Journal of surgical research.
[48] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[49] L. Holmberg,et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening , 2006, Acta oncologica.
[50] K. Camphausen,et al. Early ipsilateral breast tumor recurrences after breast conservation affect survival: an analysis of the National Cancer Institute randomized trial. , 2005, International journal of radiation oncology, biology, physics.
[51] M. Sliwkowski,et al. Evolution of the MDA-MB-175 breast cancer cell line from a low to a high HER2 expressing tumor line , 2005 .
[52] S. Steinberg,et al. Eighteen‐year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy , 2003, Cancer.
[53] P. Hall,et al. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women , 2003, BMJ : British Medical Journal.
[54] B. E. F. Isher,et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .
[55] Anthony Rhodes,et al. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. , 2002, American journal of clinical pathology.
[56] T. Lumley,et al. Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.
[57] J. Coindre,et al. Application of the Van Nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examinated by serial macroscopic sectioning: Practical considerations , 2000, Breast Cancer Research and Treatment.
[58] R. Arriagada,et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] F. Vicini,et al. Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma in Situ (DCIS) of the Breast in a Randomized Clinical Trial (SweDCIS) , 2021, Social Science Research Network.
[60] Rhona J. Souers,et al. Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories. , 2013, Archives of pathology & laboratory medicine.
[61] Christopher Otis,et al. Quality assurance for design control and implementation of immunohistochemistry assays; Approved guidelinesecond edition , 2011 .
[62] L. Holmberg,et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. , 2007, European journal of cancer.
[63] H. Mouridsen,et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. , 1992, Journal of the National Cancer Institute. Monographs.
[64] George M. Nixon,et al. Practical Considerations of , 1945 .